Among the 22 breast cancer PDX models, 14, including 7 of the 8 basal tumours, harboured TP53 mutations, 5 luminal B PDXs had ESR1 mutations, and 5 luminal B and 1 CLDN-low xenografts carried PIK3CA mutations. Here, TP53 is linked to breast carcinoma.